Welcome to our dedicated page for HUTCHMED (China) news (Ticker: $HCM), a resource for investors and traders seeking the latest updates and insights on HUTCHMED (China) stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HUTCHMED (China)'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HUTCHMED (China)'s position in the market.
HUTCHMED (HCM) announced key changes in its leadership on May 17, 2024. Mr. Simon To retired from his role as Chairman and Executive Director after 23 years with the company, citing personal and health reasons. Dr. Dan Eldar, a Non-executive Director since 2016 with over 30 years of experience in various sectors, has been appointed as the new Chairman. These changes will take effect immediately. Dr. Eldar will also join the Nomination and Technical Committees, while Ms. Edith Shih will join the Remuneration Committee. Mr. To will remain a Strategic Advisor to HUTCHMED. The board expressed deep gratitude to Mr. To for his significant contributions.
HUTCHMED announced that key data from the Phase III ESLIM-01 study of sovleplenib and other hematological malignancy treatments will be presented at EHA2024. The ESLIM-01 study showed a 48.4% durable response rate for sovleplenib in primary ITP patients, significantly higher than the placebo. Safety profiles showed comparable TEAEs between sovleplenib (25.4%) and placebo (24.2%). Additional Phase II data on sovleplenib for wAIHA showed a 43.8% overall response rate in the first 8 weeks. Presentation details include various other investigational therapies like HMPL-306, HMPL-760, and tazemetostat.
HUTCHMED has commenced a Phase II/III trial exploring the efficacy of a combination therapy involving surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). The trial began on May 8, 2024, and aims to enroll 500 patients after an initial safety run-in stage, with the primary endpoint being overall survival (OS). Secondary endpoints include objective response rate (ORR), progression-free survival (PFS), and safety. PDAC is a particularly aggressive cancer with a five-year survival rate of less than 10%, and existing treatments have not shown significant improvement in patient outcomes.
HUTCHMED has initiated a Phase III clinical trial of HMPL-306 for relapsed/refractory acute myeloid leukemia (AML) patients with IDH1/IDH2 mutations in China. The trial, named RAPHAEL, started dosing the first patient on May 11, 2024. HMPL-306 is a dual-inhibitor targeting both IDH1 and IDH2 mutations, potentially overcoming resistance seen with single inhibitors. The trial aims to enroll around 320 patients and will compare HMPL-306's effectiveness and safety to current chemotherapy regimens. Key endpoints include overall survival, event-free survival, and complete remission rates. Previous Phase I data showed promising results, with more data expected in June 2024.
HUTCHMED announces the appointment of Dr. Renu Bhatia as an Independent Non-executive Director and member of the Technical Committee, bringing over 25 years of experience in healthcare, finance, fintech, and regulation. Dr. Bhatia's extensive expertise is expected to enhance the skill set and knowledge base of the Board. Her background includes roles in investment banking, asset management, venture capital, and compliance. The appointment is set to take effect on May 13, 2024.
HUTCHMED announces that its partner Takeda has received a positive CHMP opinion for fruquintinib in treating previously treated metastatic colorectal cancer in the EU. If approved, fruquintinib will be the first targeted therapy for this cancer type in over a decade. The opinion is based on results from the Phase III FRESCO-2 trial.
